2025 Q4 -tulosraportti
Vain PDF
21 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 143 | - | - | ||
| 5 | - | - | ||
| 850 | - | - | ||
| 150 | - | - | ||
| 2 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·23 min sittenTHE ASYMMETRIC CHOICE: THE RISK OF BEING OUTSIDE CIRCIO NOW 🧬⚖️ Many investors are now facing a classic psychological dilemma: "Should I secure profit? Should I wait for a dip? Can I get a cheaper entry later?" That is a rational way of thinking in a mature industrial stock. But in publicly traded platform biotech, "rational trading" can be your biggest enemy. We have now entered a phase where fundamental forces can override daily market noise in an instant. Here is the reality: In biotech, the biggest repricings rarely happen gradually. They happen brutally, unannounced and without a calendar invitation. One strategic partner update, one crucial in vivo readout, or one Big Pharma validation of the circVec platform is all it takes. When substantial data hits the market, the price doesn't move 5 % at a time – it "gaps" up because the risk in the case has fundamentally changed. You cannot trade de-risking. Either you are in when it happens, or you see the train leave the platform. Why timing is critical right now: We are in "The Red Zone". Look at the timeline unfolding now: • VWAP period (May 8–22): The price of the warrants (CRNAS) is being set now. • ASGCT Boston (May 11–15): The world elite in gene therapy gets to see the latest circVec data. • The data stack: We are waiting for in vivo evidence in heart, eye and CNS, as well as progress in the CAR-T track with Acuitas. Capital as a catalyst: The company is now rigging the financial engine through the warrant program. In biotech, cash is the same as negotiating power. A solid war chest means that Circio does not need to accept suboptimal agreements, but can sit at the table with Big Pharma with a straight back. Reality check: This is still high-risk preclinical biotech. But it is a very special type of risk to be on the sidelines in a case with this trigger stack. The market is arguing over dimes, while the industrial evidence is stacking higher and higher. The question is not whether the stock fluctuates tomorrow. The question is where you are positioned the day the platform goes from being "exciting theory" to becoming "strategic infrastructure". We know what we own. ♟️🧱🍷- ·28 min sittenSTRATEGIC TIMING OF THE CAPITAL STRUCTURE 🧬⚖️ Practical information regarding the subscription rights (warrants) with ticker CRNAS has been sent out. For those following the case fundamentally, this is an important piece in the company's financial setup. The industrial facts: • Volume: 67,680,945 warrants outstanding. • Pricing (VWAP): Occurs in the period May 8–22, 2026. • Terms: Redemption price is set with a 20 % discount to the volume-weighted average price (VWAP) in the mentioned period. • Exercise period: May 26 to June 9, 2026. • Last trading day CRNAS: June 3, 2026. Strategic timeline: It is worth noting the overlap in the timeline. The pricing period (VWAP) starts May 8. The ASGCT conference in Boston starts May 11, with the company's main presentation of the circVec platform on May 15. This means that the reference price for the capital raise is established simultaneously as the company presents its latest in vivo data to the global expertise. If the technical data confirms the platform's potential, it paves the way for a solid strengthening of the equity. Capital as a strategic tool: In biotech, liquidity is directly correlated with negotiation strength: 1. Operational runway: Funding ensures progress in the ongoing in vivo programs and the CAR-T track with Acuitas. 2. Negotiation position: A strengthened cash position signals to potential partners (Big Pharma) that the company has the endurance to develop the values internally rather than accepting suboptimal agreements early. Important clarification: Redemption of warrants requires cash payment. Rights not exercised by June 9, 2026, will lapse without compensation. The company is now gearing up to match the technical development with a robust financial platform. Focus remains on the industrial milestones and de-risking of the technology. We know what we own. ♟️🧱🍷
28 min sitten · Muokattu28 min sitten · MuokattuCheck your mail.. info about warrants
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
21 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·23 min sittenTHE ASYMMETRIC CHOICE: THE RISK OF BEING OUTSIDE CIRCIO NOW 🧬⚖️ Many investors are now facing a classic psychological dilemma: "Should I secure profit? Should I wait for a dip? Can I get a cheaper entry later?" That is a rational way of thinking in a mature industrial stock. But in publicly traded platform biotech, "rational trading" can be your biggest enemy. We have now entered a phase where fundamental forces can override daily market noise in an instant. Here is the reality: In biotech, the biggest repricings rarely happen gradually. They happen brutally, unannounced and without a calendar invitation. One strategic partner update, one crucial in vivo readout, or one Big Pharma validation of the circVec platform is all it takes. When substantial data hits the market, the price doesn't move 5 % at a time – it "gaps" up because the risk in the case has fundamentally changed. You cannot trade de-risking. Either you are in when it happens, or you see the train leave the platform. Why timing is critical right now: We are in "The Red Zone". Look at the timeline unfolding now: • VWAP period (May 8–22): The price of the warrants (CRNAS) is being set now. • ASGCT Boston (May 11–15): The world elite in gene therapy gets to see the latest circVec data. • The data stack: We are waiting for in vivo evidence in heart, eye and CNS, as well as progress in the CAR-T track with Acuitas. Capital as a catalyst: The company is now rigging the financial engine through the warrant program. In biotech, cash is the same as negotiating power. A solid war chest means that Circio does not need to accept suboptimal agreements, but can sit at the table with Big Pharma with a straight back. Reality check: This is still high-risk preclinical biotech. But it is a very special type of risk to be on the sidelines in a case with this trigger stack. The market is arguing over dimes, while the industrial evidence is stacking higher and higher. The question is not whether the stock fluctuates tomorrow. The question is where you are positioned the day the platform goes from being "exciting theory" to becoming "strategic infrastructure". We know what we own. ♟️🧱🍷
- ·28 min sittenSTRATEGIC TIMING OF THE CAPITAL STRUCTURE 🧬⚖️ Practical information regarding the subscription rights (warrants) with ticker CRNAS has been sent out. For those following the case fundamentally, this is an important piece in the company's financial setup. The industrial facts: • Volume: 67,680,945 warrants outstanding. • Pricing (VWAP): Occurs in the period May 8–22, 2026. • Terms: Redemption price is set with a 20 % discount to the volume-weighted average price (VWAP) in the mentioned period. • Exercise period: May 26 to June 9, 2026. • Last trading day CRNAS: June 3, 2026. Strategic timeline: It is worth noting the overlap in the timeline. The pricing period (VWAP) starts May 8. The ASGCT conference in Boston starts May 11, with the company's main presentation of the circVec platform on May 15. This means that the reference price for the capital raise is established simultaneously as the company presents its latest in vivo data to the global expertise. If the technical data confirms the platform's potential, it paves the way for a solid strengthening of the equity. Capital as a strategic tool: In biotech, liquidity is directly correlated with negotiation strength: 1. Operational runway: Funding ensures progress in the ongoing in vivo programs and the CAR-T track with Acuitas. 2. Negotiation position: A strengthened cash position signals to potential partners (Big Pharma) that the company has the endurance to develop the values internally rather than accepting suboptimal agreements early. Important clarification: Redemption of warrants requires cash payment. Rights not exercised by June 9, 2026, will lapse without compensation. The company is now gearing up to match the technical development with a robust financial platform. Focus remains on the industrial milestones and de-risking of the technology. We know what we own. ♟️🧱🍷
- 28 min sitten · Muokattu28 min sitten · MuokattuCheck your mail.. info about warrants
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 143 | - | - | ||
| 5 | - | - | ||
| 850 | - | - | ||
| 150 | - | - | ||
| 2 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
21 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·23 min sittenTHE ASYMMETRIC CHOICE: THE RISK OF BEING OUTSIDE CIRCIO NOW 🧬⚖️ Many investors are now facing a classic psychological dilemma: "Should I secure profit? Should I wait for a dip? Can I get a cheaper entry later?" That is a rational way of thinking in a mature industrial stock. But in publicly traded platform biotech, "rational trading" can be your biggest enemy. We have now entered a phase where fundamental forces can override daily market noise in an instant. Here is the reality: In biotech, the biggest repricings rarely happen gradually. They happen brutally, unannounced and without a calendar invitation. One strategic partner update, one crucial in vivo readout, or one Big Pharma validation of the circVec platform is all it takes. When substantial data hits the market, the price doesn't move 5 % at a time – it "gaps" up because the risk in the case has fundamentally changed. You cannot trade de-risking. Either you are in when it happens, or you see the train leave the platform. Why timing is critical right now: We are in "The Red Zone". Look at the timeline unfolding now: • VWAP period (May 8–22): The price of the warrants (CRNAS) is being set now. • ASGCT Boston (May 11–15): The world elite in gene therapy gets to see the latest circVec data. • The data stack: We are waiting for in vivo evidence in heart, eye and CNS, as well as progress in the CAR-T track with Acuitas. Capital as a catalyst: The company is now rigging the financial engine through the warrant program. In biotech, cash is the same as negotiating power. A solid war chest means that Circio does not need to accept suboptimal agreements, but can sit at the table with Big Pharma with a straight back. Reality check: This is still high-risk preclinical biotech. But it is a very special type of risk to be on the sidelines in a case with this trigger stack. The market is arguing over dimes, while the industrial evidence is stacking higher and higher. The question is not whether the stock fluctuates tomorrow. The question is where you are positioned the day the platform goes from being "exciting theory" to becoming "strategic infrastructure". We know what we own. ♟️🧱🍷
- ·28 min sittenSTRATEGIC TIMING OF THE CAPITAL STRUCTURE 🧬⚖️ Practical information regarding the subscription rights (warrants) with ticker CRNAS has been sent out. For those following the case fundamentally, this is an important piece in the company's financial setup. The industrial facts: • Volume: 67,680,945 warrants outstanding. • Pricing (VWAP): Occurs in the period May 8–22, 2026. • Terms: Redemption price is set with a 20 % discount to the volume-weighted average price (VWAP) in the mentioned period. • Exercise period: May 26 to June 9, 2026. • Last trading day CRNAS: June 3, 2026. Strategic timeline: It is worth noting the overlap in the timeline. The pricing period (VWAP) starts May 8. The ASGCT conference in Boston starts May 11, with the company's main presentation of the circVec platform on May 15. This means that the reference price for the capital raise is established simultaneously as the company presents its latest in vivo data to the global expertise. If the technical data confirms the platform's potential, it paves the way for a solid strengthening of the equity. Capital as a strategic tool: In biotech, liquidity is directly correlated with negotiation strength: 1. Operational runway: Funding ensures progress in the ongoing in vivo programs and the CAR-T track with Acuitas. 2. Negotiation position: A strengthened cash position signals to potential partners (Big Pharma) that the company has the endurance to develop the values internally rather than accepting suboptimal agreements early. Important clarification: Redemption of warrants requires cash payment. Rights not exercised by June 9, 2026, will lapse without compensation. The company is now gearing up to match the technical development with a robust financial platform. Focus remains on the industrial milestones and de-risking of the technology. We know what we own. ♟️🧱🍷
- 28 min sitten · Muokattu28 min sitten · MuokattuCheck your mail.. info about warrants
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 143 | - | - | ||
| 5 | - | - | ||
| 850 | - | - | ||
| 150 | - | - | ||
| 2 | - | - |
Välittäjätilasto
Dataa ei löytynyt